TAP EN Article Feed

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

The ASCO Post — Fri, 22 May 2026 06:09:31 +00:00

Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023.

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans

The ASCO Post — Fri, 22 May 2026 02:16:25 +00:00

A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar.

Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer

The ASCO Post — Thu, 21 May 2026 11:30:06 +00:00

Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results from a two-arm pilot randomized trial.

Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors

The ASCO Post — Thu, 21 May 2026 09:03:01 +00:00

“This large, randomized study shows that structured yoga may help relieve some of the most consistently reported and hard-to-treat issues in cancer survivorship, leading to decreased insomnia. It’s an important advance because it offers survivors, who are likely already managing multiple medications, a nonpharmaceutical solution for reducing four different side effects at once.”

GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers

The ASCO Post — Thu, 21 May 2026 07:22:29 +00:00

Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers. Investigators also found GLP-1 receptor expression was associated with overall survival, suggesting that GLP-1 signaling may be involved in the progression of these cancers.

Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer

The ASCO Post — Thu, 21 May 2026 09:01:25 +00:00

Patients with advanced prostate cancer treated with darolutamide vs enzalutamide experienced less cognitive decline, based on results from the ARACOG (AFT-47) trial.

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma

The ASCO Post — Fri, 22 May 2026 02:51:25 +00:00

Two preclinical studies suggest that mezigdomide, a cereblon E3 ligase modulatory drug, may help overcome T-cell dysfunction, a major mechanism of resistance to CAR T-cell and bispecific T-cell engager therapies in multiple myeloma.

Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?

The ASCO Post — Fri, 22 May 2026 06:33:37 +00:00

A large population-based study by Elysia M. Alvarez, MD, MPH, Associate Professor in the Department of Pediatrics at the University of California Davis Comprehensive Cancer Center, and her colleagues, investigating the treatment patterns after initial diagnosis of germ cell tumors in adolescents and young adults (AYAs) has found that whereas guideline-concordant care was associated with improved survival, a substantial proportion of these patients did not receive this care.

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

The ASCO Post — Fri, 22 May 2026 02:58:11 +00:00

Today, the FDA approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2, for adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

The ASCO Post — Fri, 22 May 2026 03:20:03 +00:00

Patient-reported outcomes (PROs) from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed advanced ovarian cancer, regardless of homologous recombination deficiency status.

From Hawaii to Health AI: A Career at the Intersection of Oncology, Data Science, and Clinical Knowledge

The ASCO Post — Fri, 22 May 2026 06:14:10 +00:00

Travis Zack, MD, PhD, Assistant Adjunct Professor at UCSF and Chief Medical Officer of OpenEvidence, speaks about about his upbringing in Hawaii, the mentors who shaped his career, his transition from academic oncology to health artificial intelligence (AI), and how he envisions generative AI changing medical education and oncology practice.